Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
A&EAccident and emergency
AEAdverse event
AHFSAmerican Hospital Formulary Service
AJCCAmerican Joint Committee on Cancer
ALCLAnaplastic large cell lymphoma
ALKAnaplastic lymphoma kinase
ASCOAmerican Society of Clinical Oncology
ASTCTAmerican Society for Transplantation and Cellular Therapy
ATCAnatomical Therapeutic Chemical
BCRPBreast cancer resistance protein
BICRBlinded independent central review
BIDTwice daily
c-MetHepatocyte growth factor receptor
C1D15Cycle 1, day 15
CADTHCanadian Agency for Drugs and Technologies in Health
CIConfidence interval
CMSCenters for Medicare & Medicaid Services
CNSCentral nervous system
COVID-19Coronavirus disease 2019
CPTCurrent Procedural Terminology
CRComplete response
CTLA4Cytotoxic T-lymphocyte-associated protein 4
CYPCytochrome P450
CYP3ACytochrome P450 3A
CYP3A4/5Cytochrome P450 3A4 and 3A5
DeCOGDermatologic Cooperative Oncology Group
DNADeoxyribonucleic acid
ECGElectrocardiogram
ECOGEastern Cooperative Oncology Group
EMAEuropean Medicines Agency
EORTCEuropean Organisation for Research and Treatment of Cancer
EQ-5DEuroQol 5-dimension instrument
EQ-5D-3LEuroQol 5-dimension 3-level instrument
EQ-5D-5LEuroQol 5-dimension 5-level instrument
ESMOEuropean Society for Medical Oncology
EUEuropean Union
EURACANEuropean Reference Network for Rare Adult Solid Cancers
FACT-GFunctional Assessment of Cancer Therapy-General
FDAFood and Drug Administration
G-BAFederal Joint Committee (Gemeinsamer Bundesausschuss)
GM-CSFGranulocyte-macrophage colony-stimulating factor
HESHospital Episode Statistics
HLAHuman leukocyte antigen
HLA-A2Human leukocyte antigen A2
ICERIncremental cost-effectiveness ratio
ICUIntensive care unit
IDIdentifier
IHPIsolated hepatic perfusion
IMTInflammatory myofibroblastic tumor
IRTInteractive response technology
LDHLactate dehydrogenase
M-PHPPercutaneous hepatic perfusion with melphalan
MAPKMitogen-activated protein kinase
MEKMitogen-activated protein kinase kinase
METMesenchymal-epithelial transition factor
MIPSMerit-based Incentive Payment System
mRNAMessenger ribonucleic acid
mUMMetastatic uveal melanoma
NAACCRNorth American Association of Central Cancer Registries
NCCNNational Comprehensive Cancer Network
NCINational Cancer Institute
NDANew Drug Application
NDCNational Drug Code
NHSNational Health Service
NHSENational Health Service England
NICENational Institute for Health and Care Excellence
NSCLCNon-small cell lung cancer
NYHANew York Heart Association
ORRObjective response rate
OSOverall survival
P-gpP-glycoprotein
PDProgressive disease
PD-1Programmed cell death protein 1
PD-L1Programmed death-ligand 1
PDQPhysician Data Query
PFSProgression-free survival
PHPPercutaneous hepatic perfusion
PI3KPhosphoinositide 3-kinase
PKCProtein kinase C
pMARCKSPhosphorylated myristoylated alanine-rich C-kinase substrate
pPKCPhosphorylated protein kinase C
PRPartial response
PSPerformance status
QALYQuality-adjusted life-year
QDOnce daily
QLQ-C30Quality of Life Questionnaire Core 30
QTcFQT interval corrected for heart rate by the Fridericia method
RDERecommended dose for expansion
RECISTResponse Evaluation Criteria in Solid Tumors
REMSRisk Evaluation and Mitigation Strategy
RONRecepteur d'origine nantais
ROS1ROS proto-oncogene 1, receptor tyrosine kinase
RTORReal-Time Oncology Review
SDStable disease; standard deviation
SEERSurveillance, Epidemiology, and End Results
SMRSociety for Melanoma Research
TCGAThe Cancer Genome Atlas
TEBETebentafusp
TRAETreatment-related adverse event
ULNUpper limit of normal
USUnited States
USAUnited States of America
USCSUnited States Cancer Statistics
WHOWorld Health Organization